Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Homology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Homology. Displaying page 1 of 1.
    EudraCT Number: 2005-000309-75 Sponsor Protocol Number: Start Date*: 2005-08-26
    Sponsor Name:Christian Geisler, Rigshospitalet, dept. Haematology 4042
    Full Title: HOVON 68 CLL: A randomized phase III study in prevously untreated patients with biological high risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab.
    Medical condition: Chronic lymphocytic leukaemia (CLL) in biological high-risk group: Unmutated and/or with deletion 17p and/or deletion 11q and/or trisomy 12.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Ongoing) FI (Completed) BE (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002714-23 Sponsor Protocol Number: LLC1114 Start Date*: 2015-01-07
    Sponsor Name:Fondazione G.I.M.EM.A. Onlus Gruppo Italiano Malattie Ematologiche dell'Adulto
    Full Title: A phase 2 multicenter study to assess the activity and the safety of front-line Ibrutinib plus Rituximab (IR) in unfit patients with Chronic Lymphocytic Leukemia (CLL).
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10024340 Leukemia lymphocytic chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022260-12 Sponsor Protocol Number: 1947 Start Date*: 2011-03-24
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: A Phase II trial of broad spectrum antibiotic therapy for early stage chronic lymphocytic leukaemia.
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006915-61 Sponsor Protocol Number: CAM-CLL1 Start Date*: 2007-04-03
    Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
    Full Title: Prospective Randomized Trial of Immediate Treatment with Campath versus Deferred Therapy in Patients with Previously Untreated Binet Stage A B-Cell Chronic Lymphocytic Leukemia at High Risk for...
    Medical condition: previously untreated Binet stage A CLL patients at high risk of disease progression
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008943 Chronic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011078-14 Sponsor Protocol Number: 09_DOG06_99 Start Date*: 2009-11-27
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: A single arm phase II study to investigate the use of Lenalidomide in the treatment of patients with early stage CLL associated with poor prognostic factors.
    Medical condition: Untreated early stage Chronic Lymphocytic Leukaemia (CLL) (Binet stage A) with poor prognostic factors.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008958 Chronic lymphocytic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003564-24 Sponsor Protocol Number: JAB-3312-1003 Start Date*: 2023-05-05
    Sponsor Name:Jacobio Pharmaceuticals Co., Ltd.
    Full Title: A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult P...
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001608-40 Sponsor Protocol Number: HS216C17(MRCT) Start Date*: 2020-07-15
    Sponsor Name:Zhejiang Hisun Pharmaceutical Co. Ltd.
    Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients with COVID-19-Moderate Type
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002873-24 Sponsor Protocol Number: RM-493-035 Start Date*: 2022-05-16
    Sponsor Name:Rhythm Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melano...
    Medical condition: Specific Gene Defects in the Melanocortin-4 Receptor Pathway, responsible for improper functions of certain messenger materials in the body. E.g Melanocyte-Stimulating Hormone (MSH)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:46:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA